SCOPOLAMINE METHYL NITRATE

380.39

380.158356

228-065-2

K0813KQM3V

TSCA listed

White to Almost white

2939.80.0000

127.94000

1.30560

Odorless, white crystalline powder.

1.31 g/cm3

199 °C

460.3ºC at 760 mmHg

232.2ºC

-25 ° (C=1, H2O)

almost transparency in Water

ODORLESS

TASTELESS

0.05% AQ SOLN IS ACIDIC (PH: 5-5.4)

III

6.1

UN15446.1/PG3

3

T,T+

36/37/39-45-25

YM3675150

T,T+

23/24/25-26/27/28

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

UN 1544 6.1/PG 3

|Danger|H300 (97.56%): Fatal if swallowed [Danger Acute toxicity, oral]|P260, P262, P264, P270, P271, P280, P284, P301+P310, P302+P350, P304+P340, P310, P320, P321, P322, P330, P361, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 41 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Parasympatholytics|ANTICHOLINERGIC FOR FUNCTIONAL DIARRHEA TREATMENT|ANTICHOLINERGIC FOR BOWEL HYPERMOTILITY TREATMENT|ANTICHOLINERGIC FOR PEPTIC ULCER TREATMENT|ANTICHOLINERGIC, ANTISPASMODIC & ANTISECRETORY AGENT

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)

MAJOR ACTION OF ANTIMUSCARINIC AGENTS IS COMPETITIVE OR SURMOUNTABLE ANTAGONISM TO ACETYLCHOLINE AND OTHER MUSCARINIC AGONISTS. /ANTIMUSCARINIC AGENTS/

IN NORMAL PEOPLE SC INJECTION OF 1 MG HAS CAUSED MYDRIASIS & CYCLOPLEGIA LASTING SEVERAL HR, BUT 0.5 MG SC OR IM HAS HAD LITTLE OR NO EFFECT ON ACCOMMODATION, & 16 MG ORALLY HAS HAD NO EFFECT.

Bromide, N-Methylscopolamine

Dykatuss Unicells (Reid-Provident) each capsule contains chlorpheniramine maleate 8 mg, phenylephrine hydrochloride 20 mg, and methscopolamine nitrate 2.5 mg.|Infadorm Drops (Reid-Provident) contains 0.3 mg methscopolamine nitrate, phenobarbital sodium 8 mg, and secobarbital sodium 4 mg with alcohol.|Sinusule Tied Release Capsules (ICN Bentex) each capsule contains chlorpheniramine maleate 8 mg, phenylephrine hydrochloride 20 mg, and methscopolamine nitrate 2.5 mg.|Trihista-phen capsules (Recsei Labs) each capsule contains chlorpheniramine maleate 8 mg, phenylephrine HCl 20 mg, and scopolamine methylnitrate 2.5 mg.|For more Formulations/Preparations (Complete) data for METHYLSCOPOLAMINE NITRATE (18 total), please visit the HSDB record page.

HPLC DETERMINATION OF COMPOUNDS INCLUDING METHSCOPOLAMINE NITRATE IN FILM-SEALED TABLETS.|An HPLC method for the simultaneous determination of methylscopolamine nitrate, phenylpropanolamine HCl, pyrilamine maleate and pheniramine maleate was developed.